Achillion Pharmaceuticals Inc. (Nasdaq: ACHN) reported that all 12 patients in a midstage clinical trial of its hepatitis C treatment ACH-3102 remained HCV RNA undetectable four weeks after completing therapy. The stock price gained 76 cents to $9.20.
Achillion reports positive interim results
August 15, 2014 at 12:16 PM EDT
